Sleep Apnea
Obstructive sleep apnea affects 20-40% of obese adults and significantly increases cardiovascular risk. Weight loss from GLP-1s often dramatically improves or resolves sleep apnea.
AHI reduction
25-50%
CPAP elimination possible
30-40%
Improvement timeline
6-9 months
Condition Guide
Sleep Apnea
How GLP-1 Medications Help
GLP-1 medications reduce sleep apnea severity through multiple mechanisms. Weight loss of 10-15% typically reduces AHI (apnea-hypopnea index) by 25-50%. Reduced neck circumference decreases airway collapse. Improved metabolic health reduces inflammation in upper airway tissues. Many patients find they can reduce or eliminate CPAP use after significant weight loss. Even partial improvement makes CPAP therapy more tolerable and effective. The cardiovascular risk reduction from treating both sleep apnea and obesity is substantial.
Monitoring and Expectations
Baseline sleep study (polysomnography) documents starting severity. Repeat study after 20-30 pounds of weight loss to assess improvement. Many patients see significant improvement within 6-9 months. SeraVia formulations support energy and recovery during the weight loss phase. Coordination with sleep medicine specialists ensures safe CPAP adjustments.
Frequently Asked Questions
Will I still need CPAP after losing weight on GLP-1s?
30-40% of patients can eliminate CPAP after significant weight loss. Others need reduced pressures. Repeat sleep study required before stopping CPAP.
SeraVia Energy+ Boost supports daytime energy while adjusting to CPAP or during weight loss phase.
Learn More →Find sleep apnea and weight management specialists
Compare pricing, reviews, and availability across 18,000+ GLP-1 providers.
Search Providers →Explore all conditions
Learn how GLP-1 medications treat different conditions — from diabetes to PCOS to cardiovascular disease.